Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded at StockNews.com

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday.

A number of other research firms have also recently issued reports on AMRX. Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a report on Friday, September 6th. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Finally, Barclays boosted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Trading Up 5.4 %

Shares of NASDAQ AMRX traded up $0.47 during trading hours on Monday, hitting $9.20. 2,220,320 shares of the company traded hands, compared to its average volume of 1,409,931. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -13.53 and a beta of 1.17. The company’s 50 day moving average price is $8.53 and its 200 day moving average price is $7.56. Amneal Pharmaceuticals has a 12 month low of $4.15 and a 12 month high of $9.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The company had revenue of $701.78 million during the quarter, compared to analysts’ expectations of $657.43 million. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.52 EPS for the current year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently made changes to their positions in AMRX. Rothschild Investment LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $26,000. Gladius Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $37,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $42,000. Atlanta Consulting Group Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth $61,000. Finally, nVerses Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $62,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.